Scandinavian ChemoTech´s Animal Care division receives the final order confirmation from Australia for leading equine centre research project
After having secured ethics approval for a case series at Agnes Banks Equine Clinic, an Apiam Animal Health Centre, which was communicated in February 2023, Vetiqure AB´s distributor in Australia, Gamma Gurus, has confirmed a purchasing order of EUR 15,000 for a vetIQure™ demo and research system. The value of the order is higher than previously anticipated.
The order delivery and training are scheduled to take place in the beginning of May. The training includes three veterinary clinics as well as the staff at Gamma Gurus.
Agnes Banks Equine Clinic is a well-established and progressive equine veterinary practice outside Sydney. They are committed to providing routine, emergency and referral equine veterinary care and is part of Apiam Animal Health, a company that incorporates over 150 highly experienced, industry-leading veterinarians with expertise across the pig, dairy, feedlot, sheep, poultry, equine, and companion animals’ sectors, supported by an experienced administration, nursing, technical services and ancillary team.
“We are thrilled to start our operations in Australia with Gamma Gurus, a very strategic market. The confirmed order and follow-up training with well-established player such as Agnes Banks makes for a good entry and will give us the possibility to advance talks with other similar players via our cooperation with Gamma Gurus”, says Mohan Frick, CEO of Scandinavian ChemoTech.
As Gamma Gurus also presently evaluate the market access strategy for IQwave™ in Human Care, visits and introductions to university hospitals are also being planned for. The purpose is to discuss the hospital´s potential involvement in the international collaboration for deep seated tumors that ChemoTech has initiated after the successful pancreatic cancer cases in Ukraine.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.